226 related articles for article (PubMed ID: 25315258)
21. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma.
Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H;
Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266
[TBL] [Abstract][Full Text] [Related]
22. Axitinib in the Treatment of Head and Neck Malignancies.
Swiecicki PL; Spector M; Worden FP
Curr Clin Pharmacol; 2016; 11(2):72-6. PubMed ID: 27188575
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
Bondarenko IM; Ingrosso A; Bycott P; Kim S; Cebotaru CL
BMC Cancer; 2015 May; 15():339. PubMed ID: 25929582
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
25. Axitinib: VEGF inhibition in advanced thyroid cancer.
Bagcchi S
Lancet Oncol; 2014 Jul; 15(8):e310. PubMed ID: 25121176
[No Abstract] [Full Text] [Related]
26. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
Qi WX; He AN; Shen Z; Yao Y
Br J Clin Pharmacol; 2013 Sep; 76(3):348-57. PubMed ID: 23617405
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Spano JP; Moore MJ; Pithavala YK; Ricart AD; Kim S; Rixe O
Invest New Drugs; 2012 Aug; 30(4):1531-9. PubMed ID: 21670972
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
[TBL] [Abstract][Full Text] [Related]
29. A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
Chan SL; Yeo W; Mo F; Chan AWH; Koh J; Li L; Hui EP; Chong CCN; Lai PBS; Mok TSK; Yu SCH
Cancer; 2017 Oct; 123(20):3977-3985. PubMed ID: 28640364
[TBL] [Abstract][Full Text] [Related]
30. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Rini BI; Melichar B; Ueda T; Grünwald V; Fishman MN; Arranz JA; Bair AH; Pithavala YK; Andrews GI; Pavlov D; Kim S; Jonasch E
Lancet Oncol; 2013 Nov; 14(12):1233-42. PubMed ID: 24140184
[TBL] [Abstract][Full Text] [Related]
31. The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Voss MH; Bhatt RS; Plimack ER; Rini BI; Alter RS; Beck JT; Wilson D; Zhang X; Mutyaba M; Glasser C; Attie KM; Sherman ML; Pandya SS; Atkins MB
Clin Cancer Res; 2017 Jul; 23(14):3557-3565. PubMed ID: 28031424
[No Abstract] [Full Text] [Related]
32. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Spano JP; Chodkiewicz C; Maurel J; Wong R; Wasan H; Barone C; Létourneau R; Bajetta E; Pithavala Y; Bycott P; Trask P; Liau K; Ricart AD; Kim S; Rixe O
Lancet; 2008 Jun; 371(9630):2101-8. PubMed ID: 18514303
[TBL] [Abstract][Full Text] [Related]
33. Axitinib: a review in advanced renal cell carcinoma.
Keating GM
Drugs; 2015 Nov; 75(16):1903-13. PubMed ID: 26487541
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Ioka T; Okusaka T; Ohkawa S; Boku N; Sawaki A; Fujii Y; Kamei Y; Takahashi S; Namazu K; Umeyama Y; Bycott P; Furuse J
Jpn J Clin Oncol; 2015 May; 45(5):439-48. PubMed ID: 25647781
[TBL] [Abstract][Full Text] [Related]
35. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Kindler HL; Ioka T; Richel DJ; Bennouna J; Létourneau R; Okusaka T; Funakoshi A; Furuse J; Park YS; Ohkawa S; Springett GM; Wasan HS; Trask PC; Bycott P; Ricart AD; Kim S; Van Cutsem E
Lancet Oncol; 2011 Mar; 12(3):256-62. PubMed ID: 21306953
[TBL] [Abstract][Full Text] [Related]
36. Axitinib: in advanced, treatment-experienced renal cell carcinoma.
Yang LP; McKeage K
Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347
[TBL] [Abstract][Full Text] [Related]
37. Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.
Oya M; Tomita Y; Fukasawa S; Shinohara N; Habuchi T; Rini BI; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Uemura H
Cancer Sci; 2017 Jun; 108(6):1231-1239. PubMed ID: 28267243
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
Cella D; Escudier B; Rini B; Chen C; Bhattacharyya H; Tarazi J; Rosbrook B; Kim S; Motzer R
Br J Cancer; 2013 Apr; 108(8):1571-8. PubMed ID: 23579211
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.
Kang YK; Yau T; Park JW; Lim HY; Lee TY; Obi S; Chan SL; Qin S; Kim RD; Casey M; Chen C; Bhattacharyya H; Williams JA; Valota O; Chakrabarti D; Kudo M
Ann Oncol; 2015 Dec; 26(12):2457-63. PubMed ID: 26386123
[TBL] [Abstract][Full Text] [Related]
40. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]